{"id":31284,"date":"2025-03-17T17:26:00","date_gmt":"2025-03-17T11:56:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=31284"},"modified":"2025-09-15T10:18:36","modified_gmt":"2025-09-15T04:48:36","slug":"novo-vs-eli-lilly-in-anti-obesity-drug-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market","title":{"rendered":"Novo Nordisk vs. Eli Lilly: The Battle for Anti-Obesity Drug Market Dominance"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d8d579a38fa\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d8d579a38fa\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market\/#Obesity_Drug_Market_Overview_and_Growth_Potential\" >Obesity Drug Market Overview and Growth Potential<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market\/#Novo_Nordisk_The_Pioneer_in_GLP-1_Therapy\" >Novo Nordisk: The Pioneer in GLP-1 Therapy<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market\/#SAXENDA%E2%80%94Key_Asset_in_Novo_Nordisk_Obesity_Market\" >SAXENDA\u2014Key Asset in Novo Nordisk Obesity Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market\/#WEGOVY%E2%80%94Star_Performer_in_Novo_Nordisk_Obesity_Market\" >WEGOVY\u2014Star Performer in Novo Nordisk Obesity Market&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market\/#Whats_Next_in_Novo_Nordisk_Obesity_Pipeline\" >What\u2019s Next in Novo Nordisk Obesity Pipeline?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market\/#Eli_Lilly_The_Challenger_with_a_Dual-Action_Advantage\" >Eli Lilly: The Challenger with a Dual-Action Advantage<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market\/#ZEPBOUND%E2%80%94Eli_Lillys_Weight_Loss_Medication_Contender\" >ZEPBOUND\u2014Eli Lilly\u2019s Weight Loss Medication Contender&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market\/#Eli_Lilly_Obesity_Pipeline_Key_Candidates_to_Watch\" >Eli Lilly Obesity Pipeline: Key Candidates to Watch<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market\/#ZEPBOUND_vs_WEGOVY_Which_Weight_Loss_Drug_Reigns_Supreme\" >ZEPBOUND vs. WEGOVY: Which Weight Loss Drug Reigns Supreme?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market\/#Conclusion\" >Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>The global obesity crisis has sparked a multibillion-dollar showdown in the pharmaceutical world, with Novo Nordisk and Eli Lilly locked in an intense battle for supremacy. These industry titans are redefining the weight loss drug market with groundbreaking GLP-1 therapies. <strong>Novo Nordisk\u2019s WEGOVY<\/strong> <strong>(semaglutide)<\/strong> and <strong>Eli Lilly\u2019s ZEPBOUND (tirzepatide)<\/strong> are reshaping the <a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-market\">anti-obesity drug market<\/a>\u2014but which powerhouse will claim the top spot in this high-stakes race?<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-obesity-drug-market-overview-and-growth-potential\"><span class=\"ez-toc-section\" id=\"Obesity_Drug_Market_Overview_and_Growth_Potential\"><\/span><strong>Obesity Drug Market Overview and Growth Potential<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The US obesity drug market is on a meteoric rise, projected to soar past <strong>USD 73 billion<\/strong> by 2034. This explosive growth is driven by surging obesity rates, a paradigm shift in medical perception\u2014from lifestyle choice to chronic disease\u2014and groundbreaking pharmaceutical advancements.<\/p>\n\n\n\n<p>Obesity drug market leaders Novo Nordisk and Eli Lilly are in an intense race, ramping up investments in manufacturing, obesity drug clinical trials, and regulatory approvals to dominate this booming sector. With over <strong>138 million<\/strong> people in the US affected by obesity and increasing demand for effective treatments, the market is witnessing unprecedented expansion.<\/p>\n\n\n\n<p>Beyond Novo and Eli Lilly, companies such as <strong>Boehringer Ingelhium, Pfizer, Roche, AstraZeneca, Regor therapeutics, Viking Therapeutics, Amgen, BioAge Labs, Gan &amp; Lee Pharmaceuticals, Sun Pharma, Innovent Biologics, Aphaia Pharma, Vertex Pharmaceuticals<\/strong>, and others are entering the space, fueling new innovations in <a href=\"https:\/\/www.delveinsight.com\/report-store\/glucagon-like-peptide1-glp1-agonists-market-forecast\">GLP-1 therapies<\/a>, combination therapies, and next-gen metabolic treatments. As governments and insurers recognize the economic and healthcare burden of obesity, coverage and accessibility are set to improve, further accelerating market adoption.<\/p>\n\n\n\n<p>With no signs of slowing down, the anti-obesity drug market is emerging as one of the most lucrative frontiers in modern medicine\u2014a multi-billion-dollar revolution reshaping the future of healthcare.<\/p>\n\n\n\n<p><strong><em>Wondering which is the best weight loss drug? Find out at \u201c<\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape\"><strong><em>Obesity: A Worldwide Pandemic with Advancing Management Options<\/em><\/strong><\/a><strong><em>.\u201d<\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novo-nordisk-the-pioneer-in-glp-1-therapy\"><span class=\"ez-toc-section\" id=\"Novo_Nordisk_The_Pioneer_in_GLP-1_Therapy\"><\/span><strong>Novo Nordisk: The Pioneer in GLP-1 Therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Novo Nordisk, the pharmaceutical giant, revolutionized weight loss treatment by pioneering GLP-1 receptor agonists. With decades of expertise in diabetes and metabolic disorders, the company turned its innovation engine toward tackling obesity. Its blockbuster drug, <strong>OZEMPIC (semaglutide)<\/strong>, transformed diabetes care, while its higher-dose counterpart, <strong>WEGOVY<\/strong>, became a game-changer in weight management. As demand for these treatments skyrockets, Novo continues to push the boundaries, investing in new weight loss medications and reshaping the future of metabolic health. Apart from WEGOVY, <strong>SAXENDA<\/strong>, another Novo Nordisk weight loss drug, is also approved in the US for obesity.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-saxenda-key-asset-in-novo-nordisk-obesity-market\"><span class=\"ez-toc-section\" id=\"SAXENDA%E2%80%94Key_Asset_in_Novo_Nordisk_Obesity_Market\"><\/span><strong>SAXENDA\u2014Key Asset in Novo Nordisk Obesity Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Novo Nordisk weight loss drug, SAXENDA (liraglutide), is a GLP-1 receptor agonist designed to support long-term weight loss when combined with a reduced-calorie diet and increased physical activity. It\u2019s prescribed for adults with obesity (BMI \u226530 kg\/m\u00b2) or those who are overweight (BMI \u226527 kg\/m\u00b2) with at least one weight-related condition, such as hypertension, type 2 diabetes, or dyslipidemia. It\u2019s also approved for pediatric patients (12+ years, \u226560 kg) with severe obesity, based on international standards.<\/p>\n\n\n\n<p>The recommended SAXENDA daily dose is 3 mg, with a gradual dose escalation starting at 0.6 mg per day and increasing weekly to minimize side effects. Pediatric patients may require up to eight weeks to reach the full dose, with the option to adjust if needed. In 2024, SAXENDA generated sales of <strong>USD 345 million<\/strong> in the US.<\/p>\n\n\n\n<p>While SAXENDA has been a trusted option for weight management, WEGOVY\u2014another Novo Nordisk weight loss drug\u2014has entered the market with a higher efficacy profile and a once-weekly injection (compared to SAXENDA\u2019s daily dose). Clinical studies suggest that WEGOVY leads to greater weight loss, making it a strong competitor. However, SAXENDA remains a well-established choice with a longer history of use and a flexible dosing regimen that may suit certain patients better.<\/p>\n\n\n\n<p><strong><em>Read our blog \u201c<\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/transforming-obesity-treatment\"><strong><em>The Race to Redefine Obesity Treatment<\/em><\/strong><\/a><strong><em>\u201d and discover why WEGOVY is winning in the WEGOVY versus SAXENDA battle<\/em><\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-wegovy-star-performer-in-novo-nordisk-obesity-market-nbsp\"><span class=\"ez-toc-section\" id=\"WEGOVY%E2%80%94Star_Performer_in_Novo_Nordisk_Obesity_Market\"><\/span><strong>WEGOVY\u2014Star Performer in Novo Nordisk Obesity Market&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>As obesity continues to be a growing global health concern, WEGOVY has emerged as a game-changer in weight management. Developed by Novo Nordisk, WEGOVY (semaglutide) is a GLP-1 receptor agonist designed to support sustainable weight loss when paired with a balanced diet and regular physical activity. At an annual cost of ~17K, this once-weekly injection offers a convenient option for adults with obesity (BMI \u226530) or those who are overweight (BMI \u226527) with related health conditions, helping them achieve and maintain weight loss.<\/p>\n\n\n\n<p>By mimicking the body\u2019s natural GLP-1 hormone, WEGOVY influences appetite regulation, promoting a feeling of fullness and reducing caloric intake. Its dosing regimen starts gradually, increasing over time to the full 2.4 mg maintenance dose. Administered subcutaneously, it fits seamlessly into daily routines, requiring just a single injection per week.<\/p>\n\n\n\n<p>Common adverse reactions (adults and pediatric patients \u226512 years) and WEGOVY side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis.<\/p>\n\n\n\n<p>Since its US FDA approval in June 2021 and subsequent EU and Japan approval in 2022 and 2023, respectively, for chronic weight management, WEGOVY has rapidly gained traction. In March 2024, it became the first obesity medication to receive FDA approval for reducing the risk of cardiovascular events, reinforcing its role beyond weight loss. Now available in over 15 markets worldwide, WEGOVY has driven remarkable growth, generating <strong>USD 5.7 billion<\/strong> in US sales in 2024 alone.<\/p>\n\n\n\n<p>With its expanding reach and growing recognition, WEGOVY is redefining the future of obesity treatments.<\/p>\n\n\n\n<p><strong><em>Dive deep to explore the <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/wegovy-for-obesity-and-weight-loss\"><strong><em>WEGOVY effectiveness<\/em><\/strong><\/a><strong><em> in treating obesity<\/em><\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-s-next-in-novo-nordisk-obesity-pipeline\"><span class=\"ez-toc-section\" id=\"Whats_Next_in_Novo_Nordisk_Obesity_Pipeline\"><\/span><strong>What\u2019s Next in Novo Nordisk Obesity Pipeline?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Following the massive success of WEGOVY (semaglutide 2.4 mg), the company is evaluating semaglutide 7.2 mg in phase III obesity drug clinical trials. In January 2025, Novo Nordisk disclosed key findings from the <strong>STEP UP study<\/strong>, a Phase IIIb trial within the global STEP program. This 72-week study compared the efficacy and safety of subcutaneous semaglutide 7.2 mg against semaglutide 2.4 mg and a placebo, all administered weekly, in 1,407 adults with obesity who also participated in lifestyle interventions. The trial met its primary endpoint, demonstrating that semaglutide 7.2 mg led to significantly greater weight loss at week 72 compared to placebo.<\/p>\n\n\n\n<p>Another most anticipated candidate in Novo Nordisk obesity pipeline is <strong>CagriSema<\/strong>, a powerful combination of semaglutide and cagrilintide, designed to enhance appetite suppression and improve metabolic control.<\/p>\n\n\n\n<p>Beyond CagriSema, Novo Nordisk is advancing <strong>amycretin-based therapies<\/strong>, targeting dual gut hormones to amplify weight loss effects. These novel treatments aim to not only help patients shed excess weight but also improve metabolic health, reducing the risk of obesity-related conditions like diabetes and cardiovascular disease. As competition in the obesity drug market heats up, Novo Nordisk\u2019s obesity pipeline positions it as a frontrunner in delivering life-changing solutions for millions worldwide.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"464\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152549\/Promising-Candidates-in-Novo-Nordisk-Obesity-Pipeline-1024x464.png\" alt=\"Promising-Candidates-in-Novo-Nordisk-Obesity-Pipeline\" class=\"wp-image-31288\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152549\/Promising-Candidates-in-Novo-Nordisk-Obesity-Pipeline-1024x464.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152549\/Promising-Candidates-in-Novo-Nordisk-Obesity-Pipeline-300x136.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152549\/Promising-Candidates-in-Novo-Nordisk-Obesity-Pipeline-150x68.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152549\/Promising-Candidates-in-Novo-Nordisk-Obesity-Pipeline-768x348.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152549\/Promising-Candidates-in-Novo-Nordisk-Obesity-Pipeline-1536x696.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152549\/Promising-Candidates-in-Novo-Nordisk-Obesity-Pipeline-2048x928.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-eli-lilly-the-challenger-with-a-dual-action-advantage\"><span class=\"ez-toc-section\" id=\"Eli_Lilly_The_Challenger_with_a_Dual-Action_Advantage\"><\/span><strong>Eli Lilly: The Challenger with a Dual-Action Advantage<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pharma giant Eli Lilly has shaken up the anti-obesity drug market with <strong>tirzepatide<\/strong>\u2014branded as <strong>MOUNJARO <\/strong>for diabetes and <strong>ZEPBOUND <\/strong>for obesity. Unlike traditional GLP-1 drugs, tirzepatide targets both GLP-1 and GIP receptors, unlocking superior weight-loss results compared to semaglutide (OZEMPIC, WEGOVY). With game-changing clinical outcomes and skyrocketing demand, Eli Lilly is challenging Novo\u2019s dominance in the booming obesity drug market.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-zepbound-eli-lilly-s-weight-loss-medication-contender-nbsp\"><span class=\"ez-toc-section\" id=\"ZEPBOUND%E2%80%94Eli_Lillys_Weight_Loss_Medication_Contender\"><\/span><strong>ZEPBOUND\u2014Eli Lilly\u2019s Weight Loss Medication Contender&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Originally developed for type 2 diabetes, <strong>ZEPBOUND (tirzepatide), <\/strong>Eli Lilly weight loss medication, is now making waves in obesity treatment. With a sharp focus on metabolic diseases, the company is poised to lead the booming obesity market. DelveInsight projects that ZEPBOUND will claim a massive <strong>35% <\/strong>market share by 2034.<\/p>\n\n\n\n<p>ZEPBOUND injection has received FDA approval for treating adults with moderate-to-severe obstructive sleep apnea and obesity. It is also authorized for use alongside a reduced-calorie diet and increased physical activity to aid in weight loss and long-term weight management for adults with obesity or those who are overweight with at least one weight-related health condition.<\/p>\n\n\n\n<p>As the first and only dual-activating GIP and GLP-1 obesity treatment, ZEPBOUND, Eli Lilly weight loss medication, addresses a key factor contributing to excess weight by curbing appetite and reducing food intake. Common ZEPBOUND side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, allergic responses, belching, hair loss, and heartburn, though this is not an exhaustive list of potential ZEPBOUND side effects. In Q4 2024, US ZEPBOUND revenue reached <strong>USD 1.91 billion<\/strong>, a significant increase from <strong>USD 175.8 million<\/strong> in Q4 2023.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-eli-lilly-obesity-pipeline-key-candidates-to-watch\"><span class=\"ez-toc-section\" id=\"Eli_Lilly_Obesity_Pipeline_Key_Candidates_to_Watch\"><\/span><strong>Eli Lilly Obesity Pipeline: Key Candidates to Watch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Eli Lilly is at the forefront of developing innovative therapies to combat obesity, with several promising GLP-1 therapies in its pipeline. Since the majority of therapies in Eli Lilly obesity pipeline are GLP-1 based, their launch will substantially expand GLP-1 market share in the weight loss injection treatments. Eli Lilly is evaluating its lead asset, <strong>tirzepatide<\/strong>, in phase III obesity drug clinical trials for the reduction of morbidity and mortality in obesity.<\/p>\n\n\n\n<p>Another notable candidate in Eli Lilly <a href=\"https:\/\/www.delveinsight.com\/report-store\/obesity-pipeline-insight\">obesity pipeline<\/a> is <strong>retatrutide<\/strong>, a triple-hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. In a Phase II trial, retatrutide demonstrated a mean weight reduction of over 17.5% in adults without diabetes but with obesity or pre-obesity, marking a significant advancement in weight management therapies.<\/p>\n\n\n\n<p>Beyond tirzepatide and retatrutide, Eli Lilly is also investing in oral GLP-1 therapies (<strong>orforglipron<\/strong>), aiming to provide convenient, effective alternatives to injections. In June 2023, Lilly reported that Orforglipron led to an average weight loss of up to 14.7% over 36 weeks in adults with obesity or overweight based on Phase II trial results.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"585\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152614\/Promising-Candidates-in-Eli-Lilly-Obesity-Pipeline-1024x585.png\" alt=\"Promising-Candidates-in-Eli-Lilly-Obesity-Pipeline\" class=\"wp-image-31289\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152614\/Promising-Candidates-in-Eli-Lilly-Obesity-Pipeline-1024x585.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152614\/Promising-Candidates-in-Eli-Lilly-Obesity-Pipeline-300x171.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152614\/Promising-Candidates-in-Eli-Lilly-Obesity-Pipeline-150x86.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152614\/Promising-Candidates-in-Eli-Lilly-Obesity-Pipeline-768x438.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152614\/Promising-Candidates-in-Eli-Lilly-Obesity-Pipeline-1536x877.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152614\/Promising-Candidates-in-Eli-Lilly-Obesity-Pipeline-2048x1169.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>With obesity now recognized as a chronic disease requiring long-term management, these innovative drugs could transform weight loss from a struggle to a science, giving patients powerful, sustainable solutions.<\/p>\n\n\n\n<p><strong><em>Curious about the best GLP-1 drugs for weight loss? Explore our expert insights on <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/7-obesity-drugs-launch\"><strong><em>GLP-1 Agonists for Obesity<\/em><\/strong><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-zepbound-vs-wegovy-which-weight-loss-drug-reigns-supreme\"><span class=\"ez-toc-section\" id=\"ZEPBOUND_vs_WEGOVY_Which_Weight_Loss_Drug_Reigns_Supreme\"><\/span><strong>ZEPBOUND vs. WEGOVY: Which Weight Loss Drug Reigns Supreme?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Novo initially held an advantage over Lilly, as WEGOVY entered the market before Lilly\u2019s competing drug, ZEPBOUND, and secured broader insurance coverage early on. However, this early lead appears to be fading. ZEPBOUND has demonstrated greater weight loss than WEGOVY, giving it a commercial edge in GLP-1 weight loss research. Both companies have also made consistent progress in improving their drug supply.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Novo has pinned its hopes on CagriSema to counter Lilly\u2019s competitive threat. CagriSema combines semaglutide, the active ingredient in WEGOVY, with cagrilintide, a second drug. The company believed this combination could drive greater weight loss than ZEPBOUND, which functions differently.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Early weight loss trial results suggest CagriSema performs better than Wegovy alone, but it has fallen short of investor and executive expectations. In a Phase III trial targeting people with obesity but not diabetes, Novo aimed for 25% weight loss \u2014 a goal it missed in December. A smaller Phase II trial in diabetics showed 16% weight loss after 32 weeks, fueling hopes for stronger results in a longer Phase III study.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Commercializing CagriSema, if approved, could be challenging. Unlike Zepbound, which contains a single ingredient, CagriSema\u2019s two components can\u2019t be mixed together, requiring separate manufacturing and delivery via a dual-chambered pen.<\/p>\n\n\n\n<p><span id=\"docs-internal-guid-cfde6552-7fff-28dd-4ee5-a56d8aadd0fd\"><\/span><\/p>\n<div dir=\"ltr\" style=\"margin-left: 0pt;\" align=\"left\">\n<table style=\"border: none; border-collapse: collapse; table-layout: fixed; width: 468pt;\"><colgroup><col \/><col \/><col \/><\/colgroup>\n<tbody>\n<tr style=\"height: 21pt;\">\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"3\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: center; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #bfe6ff; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">WEGOVY vs. ZEPBOUND<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Feature<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Novo Nordisk (WEGOVY)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Eli Lilly (ZEPBOUND)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Weight Loss (%)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">15-17%<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">20-22%<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Mechanism of Action<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">GLP-1<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">GLP-1 &amp; GIP<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">FDA Approval<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Approved for obesity<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Approved for obesity<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Cost (per month)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">USD 1,349<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">USD 1,059<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Patient Segment<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&ge;12 years<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&ge;18 years<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Manufacturing Challenges<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Supply shortages<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Scaling up production<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Market Strategy<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Expanding production, new formulations<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: #f5f5f5; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Competitive pricing, rapid expansion<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong><em>Keen to know why Novo is leading? Read \u201c<\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/transforming-obesity-treatment\"><strong><em>WEGOVY vs. ZEPBOUND<\/em><\/strong><\/a><strong><em>\u201d and find out<\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Novo Nordisk is strengthening its dominance in the weight loss market with its well-established GLP-1 therapies, including <strong>WEGOVY and SAXENDA<\/strong>, while also developing next-generation treatments like <strong>CagriSema<\/strong>. Clinical trials have shown that WEGOVY leads to greater weight loss compared to other treatments, including Eli Lilly\u2019s <strong>ZEPBOUND<\/strong>, reinforcing its position as a top obesity treatment.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Novo\u2019s strong market presence and deep expertise in diabetes and obesity treatments have earned the trust of both healthcare providers and patients. As obesity rates continue to climb, Novo\u2019s innovative solutions give it a competitive edge over emerging rivals like Eli Lilly. Additionally, Novo\u2019s strategic management of supply chain challenges has helped maintain the consistent availability of WEGOVY and SAXENDA, boosting patient satisfaction and prescribing confidence. In contrast, Eli Lilly has faced supply issues that have affected the availability of ZEPBOUND.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Novo\u2019s acquisition of <strong>Catalent facilities<\/strong> to meet growing demand reflects a strategic move to strengthen production capacity. The company\u2019s increased R&amp;D investment\u2014up <strong>48%<\/strong>\u2014underscores its commitment to clinical innovation and expanding product indications.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Novo\u2019s pricing strategy also contributes to its market leadership. Despite premium pricing, Novo has been more effective in negotiating with insurers to improve coverage, making WEGOVY and SAXENDA more accessible to a wider patient base and increasing market share.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Novo holds a commanding position in the GLP-1 market, with nearly two-thirds of patients using its treatments, supported by robust sales growth and a positive market outlook. Sales of its obesity care products, including WEGOVY and SAXENDA, increased by <strong>56%<\/strong> in Danish kroner and <strong>57%<\/strong> at constant exchange rates (CER). Meanwhile, ZEPBOUND generated <strong>USD 1.91 billion<\/strong> in U.S. revenue in Q4 2024, a sharp rise from <strong>USD 175.8 million<\/strong> in Q4 2023.&nbsp;&nbsp;<\/p>\n\n\n\n<p>As demand for effective and reliable weight-loss solutions grows, Novo\u2019s ability to deliver strong efficacy, consistent availability, and improved affordability positions it ahead of Eli Lilly in the obesity treatment market.<\/p>\n\n\n\n<p>It will be interesting to see which company, Novo Nordisk or Eli Lilly, will reach the trillion-dollar mark first. Both have seen remarkable growth driven by the success of their diabetes and obesity treatments. With strong pipelines and expanding market opportunities, the race to a trillion-dollar valuation could reflect broader trends in the healthcare and pharmaceutical sectors.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-1024x194.png\" alt=\"Obesity-Market-Outlook-and-Assessment\" class=\"wp-image-28507\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-1568x297.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-faqs\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span>FAQs<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1757480267990\"><strong class=\"schema-faq-question\"><strong><strong>Could anti-obesity drugs eventually replace bariatric surgery?<\/strong><\/strong><\/strong> <p class=\"schema-faq-answer\">With GLP-1 therapies like WEGOVY and ZEPBOUND showing dramatic weight-loss outcomes, many wonder if they could reduce or even replace the need for bariatric surgery. While surgery still delivers the most extreme weight loss, the convenience and scalability of injectables may shift patient and physician preferences over time.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757480275393\"><strong class=\"schema-faq-question\"><strong><strong>Why are insurers hesitant to cover weight-loss drugs despite huge demand?<\/strong><\/strong><\/strong> <p class=\"schema-faq-answer\">Coverage is a bottleneck. Insurers weigh the short-term cost of GLP-1 therapies (up to ~$17K annually) against the long-term savings from reduced obesity-related complications. The hesitation lies in balancing financial risk today with future health economics.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757480285725\"><strong class=\"schema-faq-question\"><strong><strong>Can supply chain issues decide the winner of this drug war?<\/strong><\/strong><\/strong> <p class=\"schema-faq-answer\">Yes. Beyond clinical efficacy, the company that secures uninterrupted global supply and manufacturing scale could dominate the market. Recent shortages have frustrated patients, proving that logistics are as critical as innovation.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757480296408\"><strong class=\"schema-faq-question\"><strong><strong>Are GLP-1 drugs being tested for benefits beyond weight loss?<\/strong><\/strong><\/strong> <p class=\"schema-faq-answer\">Surprisingly, yes. Trials are investigating whether these drugs can reduce risks of cardiovascular disease, fatty liver, and even dementia. Their impact may extend far beyond the obesity market, opening billion-dollar side markets.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757480307802\"><strong class=\"schema-faq-question\"><strong><strong>Why are investors betting on combination therapies like CagriSema over single-drug approaches?<\/strong><\/strong><\/strong> <p class=\"schema-faq-answer\">The belief is that dual or triple-target therapies (GLP-1 + GIP + glucagon agonists) can push weight loss closer to 25\u201330%, potentially rivaling surgical results. Combination therapy could become the next competitive battleground after WEGOVY and ZEPBOUND.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757480318302\"><strong class=\"schema-faq-question\"><strong><strong>Could oral GLP-1 pills make injectables obsolete?<\/strong><\/strong><\/strong> <p class=\"schema-faq-answer\">Both companies are testing oral GLP-1 drugs. If proven equally effective, they could dramatically expand adoption, especially among patients needle-averse or unwilling to self-inject. This could disrupt the current injectable-driven market.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757911653082\"><strong class=\"schema-faq-question\"><strong>Who will hit a trillion-dollar valuation first\u2014Novo or Lilly\u2014and why does obesity matter so much to investors?<\/strong><\/strong> <p class=\"schema-faq-answer\">Obesity isn\u2019t just a therapeutic area, it\u2019s a trillion-dollar gateway to treating diabetes, heart disease, and metabolic disorders. The company that wins here could set the tone for pharma\u2019s next decade, and investors know it.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>The global obesity crisis has sparked a multibillion-dollar showdown in the pharmaceutical world, with Novo Nordisk and Eli Lilly locked in an intense battle for supremacy. These industry titans are redefining the weight loss drug market with groundbreaking GLP-1 therapies. Novo Nordisk\u2019s WEGOVY (semaglutide) and Eli Lilly\u2019s ZEPBOUND (tirzepatide) are reshaping the anti-obesity drug market\u2014but [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":31286,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[20480,22409,22481,1173,19429,20479,19427,18881,20478,19430,21050,22172],"industry":[17225],"therapeutic_areas":[18720],"class_list":["post-31284","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-drugs-for-obesity","tag-glp-1-receptor","tag-novo-nordisk-vs-eli-lilly","tag-obesity","tag-obesity-companies","tag-obesity-drugs","tag-obesity-management","tag-obesity-market","tag-obesity-pipeline","tag-obesity-treatment","tag-wegovy","tag-zepbound","industry-pharmaceutical","therapeutic_areas-nutritional-disorders-and-weight-loss"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novo Nordisk vs Eli Lilly: Who\u2019s Winning the Obesity Drug Race?<\/title>\n<meta name=\"description\" content=\"The global obesity crisis has sparked a multibillion-dollar showdown, with Novo and Eli Lilly locked in an intense battle for supremacy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk vs Eli Lilly: Who\u2019s Winning the Obesity Drug Race?\" \/>\n<meta property=\"og:description\" content=\"The global obesity crisis has sparked a multibillion-dollar showdown, with Novo and Eli Lilly locked in an intense battle for supremacy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-17T11:56:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-15T04:48:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152446\/novo-vs-eli-lilly-in-anti-obesity-drug-market.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk vs Eli Lilly: Who\u2019s Winning the Obesity Drug Race?","description":"The global obesity crisis has sparked a multibillion-dollar showdown, with Novo and Eli Lilly locked in an intense battle for supremacy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk vs Eli Lilly: Who\u2019s Winning the Obesity Drug Race?","og_description":"The global obesity crisis has sparked a multibillion-dollar showdown, with Novo and Eli Lilly locked in an intense battle for supremacy.","og_url":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-03-17T11:56:00+00:00","article_modified_time":"2025-09-15T04:48:36+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152446\/novo-vs-eli-lilly-in-anti-obesity-drug-market.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market","url":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market","name":"Novo Nordisk vs Eli Lilly: Who\u2019s Winning the Obesity Drug Race?","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152446\/novo-vs-eli-lilly-in-anti-obesity-drug-market.png","datePublished":"2025-03-17T11:56:00+00:00","dateModified":"2025-09-15T04:48:36+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The global obesity crisis has sparked a multibillion-dollar showdown, with Novo and Eli Lilly locked in an intense battle for supremacy.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757480267990"},{"@id":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757480275393"},{"@id":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757480285725"},{"@id":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757480296408"},{"@id":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757480307802"},{"@id":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757480318302"},{"@id":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757911653082"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152446\/novo-vs-eli-lilly-in-anti-obesity-drug-market.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152446\/novo-vs-eli-lilly-in-anti-obesity-drug-market.png","width":466,"height":284,"caption":"novo-vs-eli-lilly-in-anti-obesity-drug-market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757480267990","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757480267990","name":"Could anti-obesity drugs eventually replace bariatric surgery?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"With GLP-1 therapies like WEGOVY and ZEPBOUND showing dramatic weight-loss outcomes, many wonder if they could reduce or even replace the need for bariatric surgery. While surgery still delivers the most extreme weight loss, the convenience and scalability of injectables may shift patient and physician preferences over time.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757480275393","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757480275393","name":"Why are insurers hesitant to cover weight-loss drugs despite huge demand?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Coverage is a bottleneck. Insurers weigh the short-term cost of GLP-1 therapies (up to ~$17K annually) against the long-term savings from reduced obesity-related complications. The hesitation lies in balancing financial risk today with future health economics.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757480285725","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757480285725","name":"Can supply chain issues decide the winner of this drug war?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Yes. Beyond clinical efficacy, the company that secures uninterrupted global supply and manufacturing scale could dominate the market. Recent shortages have frustrated patients, proving that logistics are as critical as innovation.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757480296408","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757480296408","name":"Are GLP-1 drugs being tested for benefits beyond weight loss?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Surprisingly, yes. Trials are investigating whether these drugs can reduce risks of cardiovascular disease, fatty liver, and even dementia. Their impact may extend far beyond the obesity market, opening billion-dollar side markets.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757480307802","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757480307802","name":"Why are investors betting on combination therapies like CagriSema over single-drug approaches?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The belief is that dual or triple-target therapies (GLP-1 + GIP + glucagon agonists) can push weight loss closer to 25\u201330%, potentially rivaling surgical results. Combination therapy could become the next competitive battleground after WEGOVY and ZEPBOUND.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757480318302","position":6,"url":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757480318302","name":"Could oral GLP-1 pills make injectables obsolete?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Both companies are testing oral GLP-1 drugs. If proven equally effective, they could dramatically expand adoption, especially among patients needle-averse or unwilling to self-inject. This could disrupt the current injectable-driven market.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757911653082","position":7,"url":"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market#faq-question-1757911653082","name":"Who will hit a trillion-dollar valuation first\u2014Novo or Lilly\u2014and why does obesity matter so much to investors?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Obesity isn\u2019t just a therapeutic area, it\u2019s a trillion-dollar gateway to treating diabetes, heart disease, and metabolic disorders. The company that wins here could set the tone for pharma\u2019s next decade, and investors know it.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/17152446\/novo-vs-eli-lilly-in-anti-obesity-drug-market-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">drugs for obesity<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">GLP-1 receptor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Novo Nordisk vs. Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity companies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity management<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Obesity Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wegovy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ZEPBOUND<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">drugs for obesity<\/span>","<span class=\"advgb-post-tax-term\">GLP-1 receptor<\/span>","<span class=\"advgb-post-tax-term\">Novo Nordisk vs. Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">obesity<\/span>","<span class=\"advgb-post-tax-term\">obesity companies<\/span>","<span class=\"advgb-post-tax-term\">obesity drugs<\/span>","<span class=\"advgb-post-tax-term\">obesity management<\/span>","<span class=\"advgb-post-tax-term\">Obesity Market<\/span>","<span class=\"advgb-post-tax-term\">obesity pipeline<\/span>","<span class=\"advgb-post-tax-term\">obesity treatment<\/span>","<span class=\"advgb-post-tax-term\">Wegovy<\/span>","<span class=\"advgb-post-tax-term\">ZEPBOUND<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 7 months ago"},"absolute_dates":{"created":"Posted on Mar 17, 2025","modified":"Updated on Sep 15, 2025"},"absolute_dates_time":{"created":"Posted on Mar 17, 2025 5:26 pm","modified":"Updated on Sep 15, 2025 10:18 am"},"featured_img_caption":"novo-vs-eli-lilly-in-anti-obesity-drug-market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=31284"}],"version-history":[{"count":4,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31284\/revisions"}],"predecessor-version":[{"id":33392,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31284\/revisions\/33392"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/31286"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=31284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=31284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=31284"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=31284"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=31284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}